Adoption and Implementation of Respiratory Digital Health Solutions Post-Pandemic
Patel M, Subramanian G, Nelson E, Ngo J, Paciulli A, Humphries M.
Respiratory Drug Delivery 2022. Volume , 2022: 29-36.
Abstract:
COVID has accelerated drug and device manufacturers, providers, insurance companies, government bodies and academia into developing or adopting digital solutions for patients. Digital solutions range from electronics powered connected drug delivery devices (Enerzair® Breezhaler®), App based digital therapeutics (reSET® Pear Therapeutics) to wireless patient monitoring systems (Masimo SafetyNet). There was more progress made in remote health within the first 20 days of March 2020 than in the previous 20 years [1].
Given the increased pace of digital health solutions in the market since the onset of the pandemic, it is important to consider the full implications of their development while ensuring alignment with the various stakeholders. As digital health solutions continue to gain traction in the market, the key factor for their commercial success will be the value that they bring to end users. Pharma companies will look to deploy more digital health solutions to support patients beyond just offering a drug.
This article provides an overview of the current digital health landscape, outlines several recommendations to assess and implement solutions from the perspective of a respiratory device manufacturer and highlights projections on future industry trends.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
